Liminal Biosciences Q4 2022 Net Loss C$(4.2M)
Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.
Franco-Nevada Q4 EPS $0.86 Beats $0.82 Estimate, Sales $320.40M Beat $289.65M Estimate
Franco-Nevada (NYSE:FNV) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.82 by 4.88 percent. This is unchanged from the same period last year. The company reported
Legacy Housing Q4 EPS $0.82 Beats $0.60 Estimate, Sales $75.55M Beat $60.63M Estimate
Legacy Housing (NASDAQ:LEGH) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.60 by 36.67 percent. This is a 46.43 percent increase over earnings of $0.56 per share from the
Inspirato Q4 EPS $(0.11) Beats $(0.15) Estimate, Sales $86.63M Beat $80.77M Estimate
Inspirato (NASDAQ:ISPO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 97.52 percent increase over losses of $(4.43) per share from the
Zomedica Pharmaceuticals Q4 EPS $(0.01) Beats $(0.01) Estimate, Sales $6.16M Miss $6.20M Estimate
Zomedica Pharmaceuticals (AMEX:ZOM) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.01) by 40 percent. The company reported quarterly sales of $6.16 million which missed
Shares Of Value Retailer Five Below Are On Sale After The Bell: What’s Causing The Fall?
Five Below Inc (NASDAQ: FIVE) shares are falling in Wednesday's after-hours session after the company reported fourth-quarter results that were largely in line with estimates and issued a weak first-quarter
NACCO Industries Q4 EPS $1.84 Up From $1.07 YoY, Sales $63.53M Up From $49.10M YoY
NACCO Industries (NYSE:NC) reported quarterly earnings of $1.84 per share. This is a 71.96 percent increase over earnings of $1.07 per share from the same period last year. The company reported $63.53 million in sales
Zomedica Pharmaceuticals Q4 Sales $6.20M Inline
Zomedica Pharmaceuticals (AMEX:ZOM) reported quarterly sales of $6.20 million which met the analyst consensus estimate. This is a 51.92 percent increase over sales of $4.08 million the same period last year.
CTS Q4 EPS $0.56 Misses $0.58 Estimate, Sales $142.28M Miss $148.17M Estimate
CTS (NYSE:CTS) reported quarterly earnings of $0.56 per share which missed the analyst consensus estimate of $0.58 by 3.45 percent. This is a 14.29 percent increase over earnings of $0.49 per share from the same period
Matinas Biopharma Holdings Cash, Cash Equivalents And Marketable Securities As Of December 31, 2022 Were $28.8M Compared With $49.6M As Of December 31, 2021
Cash, cash equivalents and marketable securities as of December 31, 2022 were $28.8 million compared with $49.6 million as of December 31, 2021. Based on current projections, the Company believes its